Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
GlobeNewswire
– ARCALYST^® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
–..
– ARCALYST^® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –
–..
ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company..
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
· Pyzchiva^® approved as one of first..